References
- Navarro J T, Ribera J M, Mate J L, Granada D, Junca J, Batlle M, et al. Hepatosplenic T-Gammadelta Lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003; 44: 531–533
- Thayu M, Markowitz J E, Mamula P, Russo P A, Muinos W I, Baldassano R N. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40: 220–222
- Mittal S, Milner B J, Johnston P W, Culligan D J. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to Fludarabine and Alemtuzumab. Eur J Haematol 2006; 76: 531–534
- Lemann M, Gerard de la Valussiere F, Carbonnel F, Bouhnik Y, Bonnet J, Allez, et al. Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): long-term follow-up of patients [abstract]. Gastroenterology 1998; 114: A1020
- Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991–997
- Khan W A, Yu L, Eisenbrey A B, Crisan D, Al-Saadi A, Davis B H, et al. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am J Clin Pathol 2001; 116: 41–50
- Belhadj K, Reyes F, Farcet J P, Tilly H, Bastard C, Angonin R, et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor prognosis: report on a series of 21 patients. Blood 2003; 102: 4261–4269
- Crohn B B. Regional Ileitis. Grune and Stratton, New York 1949
- Rozen P, Flatau E, Schujman E, Gefel A. Variability of splenomegaly in Crohn's disease. Am J Gastroenterol 1977; 67: 498–493
- Lewis J D, Bilker W B, Brensinger C, Deren J J, Vaughn D J, Strom B L. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 1080–1087
- Bernstein C N, Blanchard J F, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001; 91: 854–862
- Kown J H, Farrell R J. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 2005; 56: 169–178
- Kandiel A E, Fraser A J, Korelitz B I, Brensinger C M, Lewis J D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121–1125
- Hanauer S B, Feagan B G, Lichtenstein G R, Mayer L F, Schreiber S, Colombel J F, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549
- Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study. Gut 2006; 55: 228–233
- Mackey A C, Green L, Liang L C, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265–267
- Callegari P. Vice President, medical affairs. Centocor, inc. Important safety information for Remicade (infliximab) for health care professionals. 2006, May 19
- Rosh J R, Oliva-Hemker M. Infliximab Use and Hepatosplenic T cell lymphoma: Questions to be asked and lessons learned [Editorial]. J Pediatr Gastroenterol Nutr 2007; 44: 165–167